Efficacy and safety of interferon on neonates with respiratory syncytial virus pneumonia.

Exp Ther Med

Scientific Research and Education Section, Chongqing Health Center for Women and Children, Chongqing 401120, P.R. China.

Published: December 2020

AI Article Synopsis

  • Respiratory syncytial virus (RSV) pneumonia is a major cause of hospitalization in neonates, with no specific treatments currently available.
  • The study evaluated the effectiveness of IFN-α1b in treating RSV pneumonia by comparing 126 treated neonates to 160 controls, finding no significant differences in symptoms or bacterial co-infections between the groups.
  • Results showed that the treatment group had a significantly shorter remission time for symptoms like cough and tachypnea, suggesting that IFN-α1b may be beneficial with minimal side effects.

Article Abstract

Respiratory syncytial virus (RSV) pneumonia is a leading cause of hospitalization and mortality among neonates worldwide, and there are currently no specific clinical treatments for RSV infection. Interferons (IFNs) possess broad-spectrum antiviral properties, and the present study aimed to evaluate the efficacy and safety of IFN-α1b for the treatment of neonatal RSV pneumonia. Neonates with RSV pneumonia were divided into the treatment (126 neonates) and control (160 neonates) groups, the former of which were treated with IFN. Aside from IFN administration, both groups received the same routine treatments. There were no significant differences in patient characteristics between the two groups. All neonates in the two groups displayed symptoms such as a cough (93.0%), tachypnea (90.1%), perilabial cyanosis (67.8%), choking on milk (62.9%) and moist rales (58.4%), and no significant differences in the occurrence of these symptoms were observed between the groups (P>0.05). The percentage of cases with bacterial co-infection was 66.8% (191/286), and the bacterial species in the spectrum primarily included (21.5%), (20.4%), (17.2%), (13.1%) and (9.9%). There were no significant differences in the co-infection rate or bacterial spectrum between the two groups. The remission time of cough, tachypnea, choking on milk, perilabial cyanosis, moist rales and oxygen inhalation in the treatment group was significantly lower compared with the control group (P<0.05). Although the hospitalization time in the treatment group was shorter compared with the control group, the difference was not significant. There were two patients in the treatment group that developed fever within 2-6 h after receiving IFN-α1b, though no other adverse effects were observed. In conclusion, IFN-α1b treatment improved the symptoms associated with neonatal RSV pneumonia with minimal adverse effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646691PMC
http://dx.doi.org/10.3892/etm.2020.9350DOI Listing

Publication Analysis

Top Keywords

rsv pneumonia
12
efficacy safety
8
respiratory syncytial
8
syncytial virus
8
neonates groups
8
perilabial cyanosis
8
choking milk
8
moist rales
8
neonates
6
groups
6

Similar Publications

Correlation Between Inflammatory Markers and Pathogenic Bacteria in Children's Winter Respiratory Infections in Xinjiang.

Int J Gen Med

January 2025

Department of Respiratory and Critical Care Medical Department Infectious Diseases Ward, The Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China.

Background: This study examines the distribution characteristics of pathogenic bacteria in respiratory infections and their relationship with inflammatory markers to guide clinical drug use.

Methods: We selected 120 patients with lower respiratory tract infection in the electronic medical record system of Xinjiang Provincial People's Hospital from March 2019 to March 2023 for a case-control study. Using Indirect Immunofluorescence Antibody test(IFA), blood routine, C-reactive Protein (CRP), and High-sensitivity C-reactive Protein(hsCRP), we detected nine respiratory pathogens (Respiratory syncytial virus; Influenza A virus; Influenza B virus; Parainfluenza virus; Adenovirus; Mycoplasma pneumoniae; Chlamydia pneumoniae; Legionella pneumophila type 1; Rickettsia Q) in all patients and analyzed their distribution and correlation.

View Article and Find Full Text PDF

Human Metapneumovirus (HMPV) is a re-emerging respiratory pathogen causing significant morbidity and mortality, particularly among young children, the elderly, and immunocompromised individuals. First identified in 2001, HMPV has since been recognised as a leading cause of acute respiratory tract infections (ARTIs) worldwide. Its transmission occurs through droplets, direct contact, and surface contamination, with crowded spaces and healthcare facilities serving as key environmental amplifiers.

View Article and Find Full Text PDF

: Lower airway diseases in children are one of the major causes of hospitalisation. This study aimed to evaluate the characteristics of children admitted to a tertiary pediatric hospital diagnosed with lower airway disease and to identify differences between age groups and the two years of the study. : In this single-centre retrospective observational study, demographic and clinical information about children hospitalised in the emergency pediatric ward and diagnosed with lower respiratory disease from 1 June 2021 to 30 June 2023 were retrospectively reviewed.

View Article and Find Full Text PDF

With the goal of fast and accurate diagnosis of infectious diseases, this study presents a novel electrochemical biosensor that employs a refined aptamer (C9t) for the detection of spike (S) protein SARS-CoV-2 variants in a flexible multielectrode aptasensor array with PoC capabilities. Two aptamer modifications were employed: removing the primer binding sites and including two dithiol phosphoramidite anchor molecules. Thus, reducing fabrication time from 24 to 3 h and increasing the stability and sparseness for multi-thiol aptasensors compared to a standard aptasensor using single thiols, without a reduction in aptamer density.

View Article and Find Full Text PDF

[Clinical characteristics of infants with respiratory syncytial virus infection under 3 months of age before, during, and after the SARS-CoV-2 pandemic].

Zhonghua Er Ke Za Zhi

February 2025

Department of Neonatal Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou 310052, China.

To assess the changes in epidemiologic and clinical characteristics of respiratory syncytial virus (RSV) infection among inpatient under 3 months of age with lower respiratory tract infection (LRTI) in different stages of the SARS-CoV-2 pandemic. A retrospective cohort study was conducted. Clinical data on general condition and laboratory tests were collected from 3 144 RSV-positive LRTI infants less than 3 months of age hospitalized at Children's Hospital, Zhejiang University School of Medicine from January 2017 to January 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!